The term "schizophrenia" was unclear in meaning from its beginning and has remained unclear ever since. It is long past time ...

Please provide your email address to receive an email when new articles are posted on . Cobenfy is the first antipsychotic medication to treat schizophrenia by targeting cholinergic receptors. The ...

Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience Data show TEV-'749 drug delivery technology ...

COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers ...

Credit: Bristol Myers Squibb. Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors. Data from the EMERGENT ...

--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., today presented data informing clinical strategies for switching patients to UZEDY ®, an extended-release injectable ...

How Does Cobenfy Work, and How Is It Different From Other Medicines Used to Treat Schizophrenia? An imbalance of brain chemicals called neurotransmitters may contribute to schizophrenia. Current ...

Sexual dysfunction is a common side effect of antipsychotics, but it doesn’t have to be permanent. Learn about causes, ...

Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of schizophrenia in adults. The FDA approved xanomeline and trospium chloride (Cobenfy) ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population 1 Olanzapine LAI is designed ...

Caplyta (lumateperone) is a prescription drug used to treat schizophrenia in adults. It does not come as a generic drug. Caplyta comes as an oral capsule. The active ingredient in Caplyta is ...

The following story is a composite case based on common clinical experiences, created to illustrate early warning signs of schizophrenia. Names and details have been changed to protect privacy. When ...